Today in Focus: ENPH, SIMO, LLY/NVO

Market Condition: Signs of Distribution on Indexes. Elevated VIX. Rangebound action.

Commentary: Difficult trading conditions. Limited follow through. One to two days then squat. Trade smaller, trade less, Take profits faster. Some good earnings today and solid charts. I think Earnings are the best chance for sustained moves. We are not in Story mode right now.

Upcoming Earnings:After Hours: GOOG, ARM, ELFBefore Open: BTU, CAH, HSY, IDCC

New: MPC, PYPLCurrent Positions: MPC, DECK, GLW, PYPL (short)Sells: GME (closed) GLW (trimmed)

ENPH:  Beat on earnings, Positive mgmt commentary

Key Metrics: Industry Group: Solar, Market Cap: 4.88B, Float: 125.97M, Short Interest: 22.80%, Days to Cover: 4.38, Sales Y/Y TTM: 20.97%, EPS Y/Y TTM: 226.98%, Earnings: Feb 03 AMC, Exchange: NASDAQ

Catalyst: Beat on earnings quality, miss on sequential momentum. Non-GAAP EPS crushed estimates (+31% surprise) and revenue topped consensus modestly (+1.9%), but sequential revenue declined 16% QoQ. Raised Guidance outlook. Potential Turnaround inflection. High Short interest. Looking for pullback rather than immediate gap and go.

SIMO:  Strong earnings, Raised Guidance and mentioned NVDA new Enterprise Revs

Key Metrics: Industry Group: Software - Infrastructure, Market Cap: 46.33B, Float: 320.04M Short Interest 16.51%, Days to Cover: 1.85, Exchange: NASDAQ

Catalyst: Revenue beat by 6.8% and crushed own guidance by 4.7%-9.7%; operating leverage inflection delivers 340 bps margin expansion QoQ at non-GAAP operating level; Q1 2026 guide implies $1.16B annualized run rate (+76-84% YoY). Enterprise inflection with NVDA as new customer. Tight flag chart. Looks like a stock that could lead.

LLY/NVO:  Strong Earnings vs Weak Earnings same industry.

Key Metrics: Industry Group: Drug Manufacturers - General, Market Cap: 1027.39B, Float: 851.55M, Short Interest: 0.90%, Days to Cover: 2.22, Sales Y/Y TTM: 45.41%, EPS Y/Y TTM: 120.94%, Earnings: Feb 04 BMO, Exchange: NASDAQ

Catalyst: Blowout quarter with market-dominating guidance that distances LLY from struggling peers. Revenue beat by 7.4%, EPS crushed by 13%, and 2026 guidance implies 25%+ topline growth while Novo Nordisk projects -13% decline.

Potential here that NVO is a better short today than LLY is a long. Worth considering.

Delayed Reaction Watchlist (TradingView Link)

Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.